LATEST PRICE
$987.45
H 1,003.00 · L 985.31
Vol 273K · May 18
COMPOSITE SCORE
67.3
out of 100
RECOMMENDATION
WATCH
CONFIDENCE
71%
MODULES RUN
8/8
May 18, 14:16 UTC
Top Signals
- • Profitable: Net income $7396M
- • Strong revenue growth QoQ: +12.5%
- • Positive free cash flow: $5333M
- • CEO assessment: CEO Dave Ricks has a strong track record, with over 5 years in leadership and a focus on innovation and growth.
- • Insider ownership: Moderate
Price History
showing 7 of 30 days
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| May 18, 2026 | $1,000.61 | 1,003.00 | 985.31 | $987.45 | -17.47 (-1.7%) | 273K |
| May 15, 2026 | $1,006.98 | 1,014.38 | 997.41 | $1,004.92 | -1.78 (-0.2%) | 2.8M |
| May 14, 2026 | $1,017.49 | 1,018.17 | 996.01 | $1,006.70 | -9.05 (-0.9%) | 1.8M |
| May 13, 2026 | $994.75 | 1,022.82 | 992.00 | $1,015.75 | +25.88 (+2.6%) | 3.5M |
| May 12, 2026 | $974.44 | 997.52 | 971.18 | $989.87 | +22.88 (+2.4%) | 3.0M |
| May 11, 2026 | $949.00 | 995.00 | 943.26 | $966.99 | +18.54 (+2.0%) | 3.5M |
| May 08, 2026 | $974.07 | 980.00 | 947.51 | $948.45 | -26.51 (-2.7%) | 3.6M |
Module Breakdown — May 18, 14:16 UTC
| Module | Score | Confidence | Signals |
|---|---|---|---|
| FinancialHealth |
90.0 |
85% | • Profitable: Net income $7396M • Strong revenue growth QoQ: +12.5% • Positive free cash flow: $5333M |
| Leadership |
85.0 |
65% | • CEO assessment: CEO Dave Ricks has a strong track record, with over 5 years in leadership and a focus on innovation and growth. • Insider ownership: Moderate • Consistent revenue growth and robust pipeline development. • Solid capital allocation with strategic investments in R&D. • No significant governance scandals reported. • High market trust reflected in stock performance. |
| Moat |
85.0 |
65% | • Switching costs: High | Network effects: Moderate • Brand strength: High | Market position: Dominant • Strong pipeline of patented drugs • Established market presence and reputation • High investment in R&D • Comprehensive distribution network |
| Sentiment |
78.0 |
15% | • Analysed 12 articles over 7 days (4 sentiment-scored) • Average sentiment: +0.50 — Positive: 3, Neutral: 0, Negative: 1 • Most bullish: "Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight …" (score +1.00) • Most bearish: "Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?" (score -+0.50) • Sentiment cluster: 3 positive vs 1 negative articles — strong bullish consensus (+8 bonus) |
| Momentum |
77.0 |
95% | • Golden cross: MA50 (940.12) > MA200 (922.73) • RSI elevated: 69.1 • MACD bullish crossover: 31.0103 > signal 23.9540 • Strong 20-day momentum: +9.3% |
| Institutional |
50.0 |
40% | • No insider transactions found in last 90 days (SEC EDGAR Form 4) |
| Macro |
50.0 |
15% | • Sector performance data unavailable |
| Valuation |
50.0 |
78% | • P/E ratio unavailable (negative earnings) |
Score History
showing 7 of 29 runs
| Date (UTC) | Score | Recommendation | Confidence | Modules |
|---|---|---|---|---|
| May 18, 14:16 | 67.3 | WATCH | 71% | 8 |
| May 17, 09:13 | 66.3 | WATCH | 71% | 8 |
| May 16, 12:24 | 66.3 | WATCH | 71% | 8 |
| May 15, 11:14 | 66.2 | WATCH | 72% | 8 |
| May 14, 10:09 | 67.3 | WATCH | 71% | 8 |
| May 13, 09:14 | 67.1 | WATCH | 71% | 8 |
| May 12, 09:42 | 66.4 | WATCH | 71% | 8 |